Cancer Clinical Trials for Adolescents and Young Adults

UnityPoint Clinic Urgent Care - Altoona

03 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

00 Patients
Waiting Now

Urgent Care - Ankeny

00 Patients
Waiting Now

Urgent Care - Lakeview

01 Patients
Waiting Now

Urgent Care - Merle Hay

00 Patients
Waiting Now

Urgent Care - Southglen

03 Patients
Waiting Now

Urgent Care - Urbandale

00 Patients
Waiting Now
Blank Children's Hospital

AYA Clinical Trials

General

APEC14B1: The Project:EveryChild Protocol: A Registry, Eligibility, Screening, Biology, and Outcome Study
Age: 25 years or younger

CNS

ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma 
Age: 1-21 years

ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Age: Younger than 22 years

ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors 
Germinoma arm only
Age: Younger than 22 years

Leukemia

AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-ALL Including a Stratum Evaluating Dasatinib in Patients with Ph-like TKI Sensitive Mutations
Age: Younger than 31 years

AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia. 
Age: Younger than 21 years

Lymphoma

AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Age: Younger than 19 years

ANHL12P1: A Randomized Phase II study of Brentuximab Vedotin and Crizotinib in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma

Age: Younger than 22 years

Germ Cell

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Low Risk Age: Younger than 50 years; Standard Risk Age: Younger than 25 years

Sarcoma

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Age: Younger than 51 years

ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
Age: Open in adult/peds; no age limit

ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide Alternating with Vincristine and Irinotecan Versus VAC/VI Plus Temsirolimus in Patients with Intermed. Risk Rhabdomyosarcoma
Age: Younger than 21 years

Refractory Solid Tumors

ADVL1622: Plase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule SMall-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors.

Age: Younger than 31 years

Match Trial - Younger than 22 years

APEC1621 SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

APEC1621 A: Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions

APEC1621 B: Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations

APEC1621 C: Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
APEC1621 D: Phase 2 subprotocol of LY3023414 in Solid Tumors

APEC1621 E: Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations.

APEC1621 F: Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
APEC1621 G: Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

APEC1621 H: Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes